Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global QuantiFERON World TB Day online event.

Despite the renewed attention on QuantiFERON, Qiagen’s 30-day share price return of 19.64% and year to date share price return of 17.87% both point to fading near term momentum. The 5 year total shareholder return of 20.51% underlines a weaker longer run outcome.

If this TB testing update has you thinking more broadly about diagnostics and health technology, it could be a good moment to scan for other healthcare names involved in AI assisted care using our 34 healthcare AI stocks

With Qiagen shares down roughly 18% over 90 days, trading at US$39.07 and sitting close to a 39% intrinsic discount, investors may wonder whether this weakness represents an opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 29.6% Undervalued

Qiagen's most followed valuation narrative points to a fair value of $55.46 compared to the last close at $39.07. This frames the recent pullback in a very different light.

The accelerated adoption of automation and digital workflows in both clinical and research settings, as seen with the development and imminent launch of three new high throughput, digitally connected automated sample prep systems, positions Qiagen to address increasing throughput and efficiency needs, supporting both top line growth and operating margin improvement in coming years.

Want to see what sits behind that fair value gap? The narrative leans heavily on measured revenue growth, firmer margins and a future earnings multiple that has been carefully stress tested.

Result: Fair Value of $55.46 (UNDERVALUED)

However, this hinges on research budgets and China not weakening further, since softer funding or prolonged regional pressure could quickly challenge the current growth story.

Next Steps

With a mix of optimism around potential rewards and concern about the risks that investors have flagged, this is a good time to review the details for yourself and move quickly while sentiment is still forming, then weigh up the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Qiagen has caught your attention, do not stop there. Widen your watchlist now so you are not looking back wishing you had acted sooner.

• Spot potential mispricings early and scan a curated set of 61 high quality undervalued stocks that combine quality with appealing entry points.
• Prioritize strength and resilience by zeroing in on companies filtered through the solid balance sheet and fundamentals stocks screener (39 results).
• Hunt for fresh opportunities off the beaten path with a screener containing 26 high quality undiscovered gems that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.